RGNX (Regenxbio) Short Interest


RGNX Regenxbio Inc RGNX
59 GF Score
Price $10.51
GF Value $13.81
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Regenxbio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RGNX vs LRMR, GLSI, PBYI: Short Interest Comparison

For the Biotechnology subindustry, Regenxbio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Short Interest distribution charts can be found below:

* The bar in red indicates where Regenxbio's Short Interest falls into.


RGNX
59GF Score
Regenxbio Inc RGNX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $10.51 is trading 23.9% below its estimated GF Value™ of $13.81. GuruFocus considers Regenxbio to be Modestly Undervalued.

Key valuation signals for RGNX:

  • Short Interest:
  • GF Value™: $13.81 vs. price of $10.51 (23.9% below fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
59GF Score

Get the complete analysis for RGNX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.51
Price
$13.81
GF Value